On June 3, 2022, a research and development agreement was signed in Spain between Fundación MEDINA and ilender Perú S.A.
Dr. Olga Genilloud, Scientific Director of the MEDINA Foundation and Antonio Armejo Sánchez Executive President and founding partner of ilender Perú S.A.
The Fundación MEDINA, a center of excellence in innovative drug research in Andalusia, represented by its Scientific Director, the Dr. Olga Genilloud, together with Mr. Antonio Armejo Sánchez, Executive President and founding partner of ilender Perú S.A., they signed an agreement through which they merged their Research and Development strategies. The objective of this agreement is to bring new products to the veterinary market that meet the challenges of the sector, presenting new therapeutic and preventive solutions, in the form of additives and medicines.
The MEDINA Foundation is a benchmark center for private research into natural products, established through an alliance between Merck Sharp and Dohme de España S.A., the Junta de Andalucía, and the University of Granada, focused on the discovery of new drugs and high-value products in biotechnology. It has one of the largest collections of microorganisms and a wide collection of natural product extracts, as well as automated equipment with technological platforms and unique resources such as the HTS screening center, high-capacity screening platforms and metabolomic analysis.
For your part ilender Perú S.A. is a Peruvian multinational company in the veterinary pharmaceutical sector, with 33 years dedicated to the production and marketing of products for veterinary health and animal productivity, with subsidiaries in Brazil, Bolivia, Chile, Peru, Colombia, Ecuador, Mexico, Central America and the Caribbean, Canada, U.S.A., Spain, the Middle East, Africa and Chinese. The company has a world-class model plant in the city of Lima, prepared for the manufacture of additives and veterinary therapeutics. It has its own brands and international representations among biologicals, antibacterials, antiparasitics, disinfectants, additives and equipment mainly oriented towards poultry and porcine species, providing its clients with support and technical advice.
Currently ilender Peru S.A. has a spin off, Ilender Ciencia y Tecnologia S.L., located in the Health Technology Park of Granada, Andalusia, Spain, which works on the development of food additives and probiotics of biotechnological origin, being a strategic bridge for the identification of potential veterinary products, led by Dr. Carlos Sialer Guerrero and Dr. Heidi Horna Inga, Research Directors, both with recognized international experience. This work team is complemented by the Director of the Board of Directors, Omar Romano Sforza, researcher, PhD in Biochemical Sciences. MBA in International Trade. Former Secretary General of the Argentine Biotechnology Forum.
MEDINA and ilender Peru S.A. Through this alliance, they will work together in the discovery and development of new bioactive metabolites, from microorganisms of industrial interest.
Armejo Yepez Group Press